AR075413A1 - Composiciones y metodo para usar aminopiridinas metodo para tratar la esclerosis multiple - Google Patents

Composiciones y metodo para usar aminopiridinas metodo para tratar la esclerosis multiple

Info

Publication number
AR075413A1
AR075413A1 ARP100100402A ARP100100402A AR075413A1 AR 075413 A1 AR075413 A1 AR 075413A1 AR P100100402 A ARP100100402 A AR P100100402A AR P100100402 A ARP100100402 A AR P100100402A AR 075413 A1 AR075413 A1 AR 075413A1
Authority
AR
Argentina
Prior art keywords
multiple sclerosis
aminopiridins
compositions
treat multiple
patient
Prior art date
Application number
ARP100100402A
Other languages
English (en)
Spanish (es)
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR075413(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of AR075413A1 publication Critical patent/AR075413A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ARP100100402A 2009-02-11 2010-02-12 Composiciones y metodo para usar aminopiridinas metodo para tratar la esclerosis multiple AR075413A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15167909P 2009-02-11 2009-02-11
US25956309P 2009-11-09 2009-11-09
US28587209P 2009-12-11 2009-12-11
US28895309P 2009-12-22 2009-12-22
US29925910P 2010-01-28 2010-01-28

Publications (1)

Publication Number Publication Date
AR075413A1 true AR075413A1 (es) 2011-03-30

Family

ID=42562065

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100402A AR075413A1 (es) 2009-02-11 2010-02-12 Composiciones y metodo para usar aminopiridinas metodo para tratar la esclerosis multiple

Country Status (22)

Country Link
US (3) US20120029035A1 (OSRAM)
JP (1) JP2012517449A (OSRAM)
KR (3) KR20170034452A (OSRAM)
CN (2) CN101896182A (OSRAM)
AR (1) AR075413A1 (OSRAM)
AU (2) AU2010213663A1 (OSRAM)
BR (2) BRPI1000031A2 (OSRAM)
CA (1) CA2751581A1 (OSRAM)
CL (1) CL2011001927A1 (OSRAM)
CO (1) CO6440534A2 (OSRAM)
EA (1) EA022755B1 (OSRAM)
EC (1) ECSP11011311A (OSRAM)
IL (1) IL214500A0 (OSRAM)
MX (1) MX2011008485A (OSRAM)
NI (1) NI201100155A (OSRAM)
NZ (1) NZ595046A (OSRAM)
PE (1) PE20120791A1 (OSRAM)
SG (2) SG173641A1 (OSRAM)
TN (1) TN2011000403A1 (OSRAM)
TW (2) TW201032809A (OSRAM)
UY (2) UY32444A (OSRAM)
WO (2) WO2010093839A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20150111930A1 (en) * 2013-10-23 2015-04-23 Afgin Pharma, Llc Topical regional neuro-affective therapy
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
CN102442942A (zh) * 2010-10-08 2012-05-09 天津和美生物技术有限公司 4-氨基吡啶的多晶型物及其制备和应用
EP2667869A1 (en) * 2011-01-28 2013-12-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
EP2814492A1 (en) * 2012-02-13 2014-12-24 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
WO2015118529A1 (en) * 2014-02-04 2015-08-13 Optimata Ltd. Method and system for prediction of medical treatment effect
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
WO2022124946A1 (ru) * 2020-12-10 2022-06-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые полиморфные формы 4-аминопиридина и их фармацевтическое применение
CN112914884B (zh) * 2021-01-19 2022-02-11 重庆火后草科技有限公司 通过稳态时长置信度测量睡眠状态下的体重值的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions

Also Published As

Publication number Publication date
BRPI1000030A2 (pt) 2018-02-14
AU2010213663A1 (en) 2011-09-29
CN102046174A (zh) 2011-05-04
SG10201609184PA (en) 2016-12-29
WO2010093839A1 (en) 2010-08-19
AU2016219650B2 (en) 2018-05-10
WO2010093838A1 (en) 2010-08-19
PE20120791A1 (es) 2012-07-08
NI201100155A (es) 2012-02-16
ECSP11011311A (es) 2011-10-31
UY32444A (es) 2010-09-30
KR20170034452A (ko) 2017-03-28
CO6440534A2 (es) 2012-05-15
IL214500A0 (en) 2011-09-27
TW201034665A (en) 2010-10-01
UY32445A (es) 2010-09-30
CA2751581A1 (en) 2010-08-19
KR20120000560A (ko) 2012-01-02
BRPI1000031A2 (pt) 2018-02-14
US20170319562A1 (en) 2017-11-09
US20150313886A1 (en) 2015-11-05
NZ595046A (en) 2013-10-25
EA201171043A1 (ru) 2012-02-28
AU2016219650A1 (en) 2016-09-15
US20120029035A1 (en) 2012-02-02
CN101896182A (zh) 2010-11-24
TW201032809A (en) 2010-09-16
CL2011001927A1 (es) 2012-07-20
EA022755B1 (ru) 2016-02-29
JP2012517449A (ja) 2012-08-02
TN2011000403A1 (en) 2013-03-27
MX2011008485A (es) 2011-11-04
AU2016219650C1 (en) 2018-08-23
SG173641A1 (en) 2011-09-29
KR20180114250A (ko) 2018-10-17

Similar Documents

Publication Publication Date Title
AR075413A1 (es) Composiciones y metodo para usar aminopiridinas metodo para tratar la esclerosis multiple
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
BR112014015955A8 (pt) uso terapêutico subcutâneo de inibidor de dpp-4
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
ECSP11011082A (es) Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
PH12012500968A1 (en) Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
NZ595189A (en) Combination therapy with thiocolchicine derivatives
NZ757815A (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
IN2015DN00376A (OSRAM)
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
NZ594365A (en) Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
BR112013026680A2 (pt) composto, método de tratamento de uma doença inflamatória e composição farmacêutica
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure